ArticleOncotarget2018
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Sunkyu Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
50 papers cite it
this paperpooled ittrialcites it